An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Autor: | Kazmi F; Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.) fkazmi@its.jnj.com., Yerino P; Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.)., McCoy C; Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.)., Parkinson A; Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.)., Buckley DB; Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.)., Ogilvie BW; Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.). |
---|---|
Jazyk: | angličtina |
Zdroj: | Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2018 Aug; Vol. 46 (8), pp. 1066-1074. Date of Electronic Publication: 2018 May 07. |
DOI: | 10.1124/dmd.118.081729 |
Abstrakt: | Oligonucleotides represent an expanding class of pharmacotherapeutics in development for various indications. Typically, oligonucleotides are developed with phosphorothioate linkages for the improvement of biologic stability; however, limited data are available on the potential of these molecules to cause drug-drug interactions (DDIs). In this study, four nontherapeutic oligonucleotides with either a phosphodiester or phosphorothioate linkage and partial sequences towards glutathione peroxidase or β -actin (PD-GP and PD-Ac or PT-GP and PT-Ac, respectively) were evaluated in vitro for their potential to inhibit cytochrome P450 (P450) enzymes and UGP-glucuronosyltransferases (UGTs) in both human liver microsomes (HLMs) and cryopreserved human hepatocytes (CHHs) and to inhibit select transporters in expression systems. PD-GP and PD-Ac had little to no inhibitory effect on any P450 or UGT enzymes in HLMs and CHHs, except for PD-Ac in HLMs for CYP2C19 (IC (Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.) |
Databáze: | MEDLINE |
Externí odkaz: |